Exelixis | EXEL - 股本和储备



金融业
股票价格
USD
资产
USD 2.49B
现金及等价物
USD 281.45M
销售成本
USD 20.66M
流动资产
USD 1.25B
流动负债
USD 361.93M
债务
USD 165.93M
EBIT
USD 248.41M
EBITDA
USD 255.4M
员工
1.15K
EPS每股收益
USD 0.91
股本和储备
USD 1.84B
销售毛利
USD 608.03M
债务利息支出
USD 23.4M
利息收入
USD 14.21M
市值
USD 16.78B
净收入
USD 212.05M
营业费用
USD 380.28M
营业利润
USD 248.41M
普通股股本
USD 248.89M
PE价格收益
18.02
税前利润
USD 262.68M
销售收入
USD 628.69M
销售和管理费用
USD 147.63M
股票
USD 28.73M
贸易债权人
USD 39.06M
应收帐款人
USD 322.21M


股本和储备 更改 日
Acadia Pharmaceuticals USD 1.31B 58.54M 2026-06
Agios Pharmaceuticals USD 1.03B 83.09M 2026-06
Akebia Therapeutics USD 25.02M 2.36M 2026-06
Amgen USD 11.69B 2.5B 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
Bayer EUR 29.71B 863M 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Cytokinetics USD -173.49M 653.08M 2026-06
Eisai JPY 906.56B 7.57B 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Exelixis USD 1.84B 91.99M 2026-06
Genmab DKK 5.96B 275M 2026-06
Glaxosmithkline GBP 17.42B 4.64B 2026-03
Incyte USD 6.34B 721.58M 2026-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Merck USD 41.93B 3.94B 2026-06
Moderna USD 6.76B 647M 2026-06
Nektar Therapeutics USD 576.22M 486.38M 2026-03
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Novartis USD 41.95B 3.02B 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Puma Biotechnology USD 115.27M 10.55M 2025-09
Sanofi EUR 73.14B 1.43B 2026-03
Takeda JPY 7.56T 215.7B 2026-06
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Xencor USD 503.23M 12.4M 2026-06